Japan’s Health Minister Kenichiro Ueno suggested on November 20 that the government could consider a wide range of approaches in reviewing out-of-pocket rules for so-called “OTC-like” prescription drugs, including frameworks used in past copay systems. Ueno made the remarks at…
To read the full story
Related Article
- MOF Floats New Patient Cost Scheme, Eyes Revival of Old Copay System
November 6, 2025
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





